600 related articles for article (PubMed ID: 2646005)
1. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
[TBL] [Abstract][Full Text] [Related]
2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
[TBL] [Abstract][Full Text] [Related]
4. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
[TBL] [Abstract][Full Text] [Related]
6. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Jelić S; Babovic N; Kovcin V; Milicevic N; Milanovic N; Popov I; Radosavljevic D
Melanoma Res; 2002 Feb; 12(1):91-8. PubMed ID: 11828263
[TBL] [Abstract][Full Text] [Related]
9. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Carmo-Pereira J; Costa FO; Henriques E
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1435-9. PubMed ID: 3595669
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
Koeppler H; Pflueger KH; Seitz R; Havemann K
Onkologie; 1989 Dec; 12(6):277-9. PubMed ID: 2696912
[TBL] [Abstract][Full Text] [Related]
15. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
[TBL] [Abstract][Full Text] [Related]
16. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
18. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
Thatcher N; Anderson H; James R; Davenport P; Craig P
Cancer; 1986 Jun; 57(11):2103-7. PubMed ID: 3697910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]